Shares dropped 8.2% reflecting investor disappointment with cautious forward outlook and the absence of clear near-term commercial catalysts, despite encouraging early clinical signals.

• SemiCell’s interim ALPHA-3 data showed a 58.3% MRD clearance rate versus 16.7% in the observation arm, indicating early biological activity but based on only 24 patients.
• No treatment-related hospitalizations or severe side effects were noted, supporting outpatient administration potential.
• ALLO-329 program advanced dose escalation with initial signs of clinical activity and tolerability, though still early stage.
• Management emphasized a deliberate, stepwise clinical development strategy without providing updated commercial guidance or timelines.
• The cautious tone and lack of immediate revenue drivers likely contributed to the negative stock reaction.